All In Biotech

Drug Trial Radar · NCT03493854

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jun 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Actual

Start

Jun 14, 2018

Primary completion

Jul 4, 2019

Study completion Jun 2, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Apr 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.

Conditions

  • Early Breast Cancer

Interventions

  • CyclophosphamideDrug

    Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.

  • DoxorubicinDrug

    Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.

  • DocetaxelDrug

    As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.

  • PaclitaxelDrug

    As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.

  • Pertuzumab IVDrug

    Pertuzumab will be administered as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.

  • FDC of Pertuzumab and Trastuzumab SCDrug

    The FDC of pertuzumab and trastuzumab will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.

  • Trastuzumab IVDrug

    Trastuzumab will be administered as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.

  • Trastuzumab SCDrug

    After surgery (from Cycle 9 onwards), participants in Arm A will be allowed to switch from trastuzumab IV to trastuzumab SC, at the discretion of the investigator, in the countries where trastuzumab SC is routinely used. For participants who switch, a fixed dose of 600 mg trastuzumab SC (irrespective of the patient's weight) will be administered in the adjuvant phase.

  • SurgeryProcedure

    Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.

  • Post-operative RadiotherapyRadiation

    If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).

  • Hormone TherapyDrug

    For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)Time frame: Pre-dose on Cycle 8, Day 1 (up to 21 weeks)

Locations

107 sites in 19 countries. Site status is shown where the registry gives one.

  • Maryland Oncology Hematology

    Rockville, Maryland

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Northwest Medical Specialties

    Lakewood, Washington

  • Fundación CENIT para la Investigación en Neurociencias

    Buenos Aires, Argentina

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, Argentina

  • COIBA

    Provincia de Buenos Aires, Argentina

  • Institut Jules Bordet

    Anderlecht, Belgium

  • GHdC Site Notre Dame

    Charleroi, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Clinique Ste-Elisabeth

    Namur, Belgium

  • Hospital Araujo Jorge; Departamento de Ginecologia E Mama

    Goiânia, Goiás, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Perola Byington

    São Paulo, São Paulo, Brazil

  • Royal Victoria Hospital

    Barrie, Ontario, Canada

  • Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center

    Oshawa, Ontario, Canada

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont

    Sherbrooke, Quebec, Canada

  • Masarykuv onkologicky ustav

    Brno, Czechia

  • Multiscan s.r.o.

    Pardubice, Czechia

  • ICO Paul Papin; Oncologie Medicale.

    Angers, France

  • Institut Sainte Catherine

    Avignon, France

  • CHRU Besançon

    Besançon, France

  • Institut Bergonie; Oncologie

    Bordeaux, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Curie; Oncologie Medicale

    Paris, France

  • APHP - Hospital Saint Louis

    Paris, France

  • ICO - Site René Gauducheau

    Saint-Herblain, France

  • Klinikum Augsburg; Frauenklinik

    Augsburg, Germany

  • Hochwaldkrankenhaus; Abt.Gynäkologie Geburtshilfe u.Senologie

    Bad Nauheim, Germany

  • Onkologische Schwerpunktpraxis Kurfürstendamm

    Berlin, Germany

  • St. Johannes-Hospital

    Dortmund, Germany

  • Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum

    Essen, Germany

  • Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem

    Hamburg, Germany

  • Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe

    Offenbach, Germany

  • Gynäkologie Kompetenzzentrum; Praxis Dr. med. Carsten Hielscher

    Stralsund, Germany

  • Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica

    Naples, Campania, Italy

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.